Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 291.11 mg (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; maize starch; crospovidone; colloidal anhydrous silica; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - apx-ciprofloxacin is indicated for the treatment of infections caused by susceptible organisms in the conditions listed: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying agents, additional therapy should be considered.

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

stada arzneimittel ag - norfloxacin - tablets - 400mg milligram

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

allergan australia pty ltd - ofloxacin -

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - norfloxacin -

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

stada arzneimittel ag - norfloxacin - tablets - 400mg milligram

Kanada - Inggeris - Health Canada

merck canada inc - norfloxacin - tablet - 400mg - norfloxacin 400mg - quinolones

Kanada - Inggeris - Health Canada

merck canada inc - norfloxacin - solution - 3mg - norfloxacin 3mg - antibacterials

Kanada - Inggeris - Health Canada

aa pharma inc - norfloxacin - tablet - 400mg - norfloxacin 400mg - quinolones

Kanada - Inggeris - Health Canada

teva canada limited - norfloxacin - tablet - 400mg - norfloxacin 400mg - quinolones

Kanada - Inggeris - Health Canada

sandoz canada incorporated - ofloxacin - solution - 0.3% - ofloxacin 0.3% - antibacterials